The Impact of Tyrosine Kinase Inhibitors on Stage IV Distant Renal Cell Carcinoma Overall Survival

Time

Wed, Jun 26 11:45AM
W 29

Title

The Impact of Tyrosine Kinase Inhibitors on Stage IV Distant Renal Cell Carcinoma Overall Survival

Abstract Summary

Utilization of the National Cancer Institute SEER Database and a literature review of guideline changes and pivotal clinical trials to determine the impact of new tyrosine kinase inhibitor therapy on the overall survival of renal cell carcinoma. There was a comparison of two treatment arms: (1) Cohort A: Overall Survival of Stage IV Distant RCC Patients from 2001-2003 (before TKI treatments were available) and (2) Cohort B: Overall Survival of Stage IV Distant RCC Patients from 2006-8 (after TKI treatments were available) to compare the impact of TKI therapy on overall survival. There was also an incorporated “washout period” between the years of 2004-2005 to account for pivotal Phase III clinical trials of sorafenib and sunitinib, both of which incorporated a significant number of advanced RCC patients. In order to control the two cohorts, there was a comparison of patient demographics, including but not limited to age of diagnosis, sex, and race to determine whether there was a significant difference between patient demographics in Cohort A (2001-2003) and Cohort B (2006-2008). In order to determine statistical significance between patient demographics and overall survival, the two sided z-test was employed.

Poster Presenter

Ashley R. Brower
Student, Ernest Mario School of Pharmacy ,
Rutgers University
United States

© 2015 DIA